新股消息 | 麦科奥特拟港股IPO 中国证监会要求说明历次增资及股权转让价格、定价依据及公允性

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional documentation from Maike Auto regarding its overseas listing application, focusing on capital contributions, share transfers, and compliance with regulations [1][2] Group 1: Regulatory Requirements - CSRC requires Maike Auto to clarify the pricing and fairness of past capital increases and share transfers, as well as confirm whether capital contributions have been fully paid and if there are any breaches of capital obligations [1] - The company must provide legal opinions on the ownership structure of major shareholders and whether any entities are prohibited from holding shares under relevant laws [1][2] Group 2: Company Overview - Maike Auto is a platform-based biotechnology company focused on the innovation and development of next-generation bispecific/multispecific peptide drugs, with its core product MT1013 being the world's first dual-target receptor agonist peptide drug [3] - MT1013 is primarily developed for the treatment of secondary hyperparathyroidism (SHPT) and plans to expand its indications to include conditions like chronic kidney disease-mineral and bone disorder (CKD-MBD) with osteoporosis [3] - As of September 22, 2025, MT1013 has completed its Phase II clinical trial for SHPT and is currently in a Phase III trial using cinacalcet as a positive control [3]